PanGenetics announces acquisition by Abbott of PG110 anti-NGF antibody to treat chronic pain
novembro 13, 2009
PDF 80,7 KB
DownloadDeveloping therapeutic antibodies in the field of chronic inflammation.
PanGenetics is a clinical stage company developing therapeutic antibodies in the field of chronic inflammation. Its lead program is a fully humanized anti-CD40 antibody.
Industry
Biotech
Status
Realised
Location
The Netherlands